LOS ANGELES, California and GUANGZHOU, China, August 12 /PRNewswire-FirstCall/ --
- Major Threat Treatable With StatC(TM); FDA-Approved Drugs to Begin Testing in U.S. Animal Models
An internationally renowned avian influenza expert today hailed "encouraging and exciting" results from experiments conducted by his research team. This study demonstrated impressive efficacy of a novel statin/caffeine combination, StatC(TM) in the treatment and prevention of H5N1, H1N1 and H3N2 in a mouse model.
To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/canopusbiopharma/34441/
Dr. Jiahai Lu, from the School of Public Health, Sun Yat-sen University in Guangzhou, China, has published extensively in the field of avian influenza, and has been researching the breakthrough compound StatC(TM) for the past two years on behalf of Canopus Biopharma (OTCPK:CBIA), a US corporation who discovered and patented the potential of this antiviral candidate.
"The global distribution of the highly pathogenic H5N1 avian influenza has caused the World Health Organization to show its profound concern regarding the possibility of the virus spreading from human to human in the future," stated Dr. Lu. "Furthermore, the development of resistance to two approved anti-influenza drugs, oseltamivir (Tamiflu(R)) and zanamivir (Relenza(R)), as well as the lack of adequate vaccines has increased the need of developing new antiviral drugs."
"Consequently, I am delighted to be involved in the preclinical research stage of this innovative antiviral candidate, and look forward to continuing our successful collaboration with Canopus Biopharma in this area."
Dr. Lu and his colleagues have conducted extensive animal studies with StatC(TM) against three influenza strains, H5N1 (avian influenza, bird flu), H1N1 (Spanish influenza) and H3N2 (Hong Kong influenza). StatC(TM) is a combination of two FDA approved compounds which have been re-formulated by Canopus BioPharma for the prevention and treatment of Influenza. Oseltamivir and ribavirin were used as positive controls in this study. In the H5N1 model, StatC(TM) prevented and relieved the symptoms of H5N1 infection, inhibited lung damage and H5N1 virus replication in the lungs of mice, and was as effective as oseltamivir in both prevention and therapy models. There were no animals with positive viral detection in the groups nasally administered with StatC(TM). Likewise, StatC(TM) demonstrated similar results against the H3N2 and H1N1 viruses.
"We are encouraged with these findings," said Dr. Lu. "It is possible that higher doses of statin than those used in this study may result in even greater efficacy. StatC(TM) also appeared to be more effective when administered preventatively." With current positive results, Canopus BioPharma is looking to form a co-development agreement or licensing arrangements with pharmaceutical companies and Government health authorities interested in providing more economical and universal treatment for their populations in the event of a pandemic.
At the forefront of influenza research in Guangzhou, China, Dr. Lu is perfectly placed to further investigate the synergistic properties of the statin/caffeine combination. "We are also motivated at the potential of this compound in comparison with other currently available anti-influenza medications. It's clear that there is significant global need for a superior, low cost and plentiful alternative in the fight against influenza." added Dr. Lu. While StatC(TM) has proven to be highly efficacious against the most virulent strains of influenza, it must be noted that StatC(TM) is also extremely effective against non-fatal, human forms of the virus that occur annually.
Approved by the Food and Drug Administration, oseltamivir (Tamiflu(R)) is the leading prescription medicine approved for the prevention and treatment of influenza in adults and children. Datamonitor, the world's leading provider of online data, analytic and forecasting platforms for key vertical sectors, forecasts that global market demand for influenza treatments will expand to 370 million doses and a market value of approximately $3.7 billion by 2010.
Canopus BioPharma's strategy for developing StatC(TM) includes continued animal testing in partnership with its extensive network of American and Chinese based research laboratories. The next step involves a ferret animal model using a lethal strain of influenza to examine the efficacy of StatC(TM). Once completed, Canopus BioPharma's preclinical results will then satisfy the FDA's Animal Efficacy Rule and will make StatC(TM) available for Government stockpiling for use in the case of a pandemic.
About Canopus BioPharma, Inc.:
Canopus BioPharma, Inc. (OTCPK:CBIA) is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods in the areas of infectious disease, radiation protection, cancer, and addiction. With innovative science, proven research and development leadership, and superior products and compounds, Canopus BioPharma has, since 2001, been committed to becoming a market trend setter in a new era of healthcare. In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers, particularly for food chain protection applications. Canopus maintains staff in Australia, South Africa, Ireland and the USA. Additional information on the Company is available at http://www.canopusbiopharma.com.
Canopus BioPharma Inc Disclaimer:
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts commercialize or attain acceptable clinical results for its products. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts and research and development programs, uncertainties as a result of research and development, consumer and industry acceptance, litigation and/or court proceedings, regulatory risks including approval of Food and Drug Administration filings, the ability to achieve and maintain revenues and profitability in the Company's business lines, and other factors discussed in the Company's filings with the Securities and Exchange Commission
SOURCE Canopus Biopharma INC
